Despite a broad understanding of the molecular and genetic complexity of acute myeloid leukemia (AML), the only immune therapy known to provide a significant improvement in outcome over standard chemotherapy is allogeneic hematopoietic stem cell transplant (HSCT). However, many patients, especially the elderly, are not eligible for allogeneic HSCT because of the rigorous conditioning and complications from the treatment, including serious and sometimes fatal graft-versus-host disease (GVHD). The 5-year survival rates in elderly AML patients (⩾65 years) are below 10%. 1 Moreover, certain molecular aberrations associated with AML, such as the FLT3 internal tandem duplication (ITD) and FLT3 point mutations have an especially adverse prognosis and a high probability of relapse. [2] [3] [4] Therefore, novel approaches for the treatment of AML represent an unmet therapeutic need.
Recently, the genetic modification of T cells with chimeric antigen receptors (CARs) that directly target tumor-associated antigens has shown success in the clinic when targeting CD19 in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). 5 However, identification of tumor-associated surface antigens that can be targeted by CAR immune cells for the treatment of cancer such as AML has proven to be challenging.
FLT3 is a member of the class III receptor tyrosine kinases, and its variable expression can be found on leukemia blasts from over 90% AML patients, 6 ,7 regardless of CD34 expression ( Figure 1a ). Approximately 20% of 30 samples of newly diagnosed AML patients, who consented to our protocol approved by the OSU institutional review board, with detailed clinical information that we screened showed nearly uniform high-density surface expression of FLT3, that is, 90% blasts are positive for FLT3 expression with high level of median fluorescence intensity (Figure 1a and Supplementary Table  1) . FLT3 is expressed on~50% of normal hematopoietic stem cells (HSCs) and partially on dendritic cells but is largely not expressed on lymphocytes in cord blood (Supplementary Figure 1) . We therefore engineered primary T cells of healthy donors to express a FLT3-specific, second-generation CAR harboring CD28, a co-stimulatory signaling domain and CD3ζ. Sequences for variable regions of heavy (VH) and light (VL) chains were originally derived from a hybridoma. 8 The VH-linker-VL fragment was incorporated in frame with the CD28-CD3ζ portion (Figure 1b) . The entire anti-FLT3-scFv-CD28-CD3ζ fragment was then subcloned into the lentiviral vector pCDH. Next, we performed lentiviral transduction of primary T cells with the generated FLT3-CAR construct. The generated CAR T cells were lysed in laemmli buffer. Lysates were separated by SDS-PAGE gel and transferred to a PVDF membrane. The membrane was immunoblotted with mouse anti-human CD3ζ mAb and then with a horseradish peroxidase-conjugated goat anti-mouse IgG antibody. Immunoblotting results showed that the CAR was selectively expressed in the T cells (Figure 1c) . To detect the expression of FLT3-CAR, especially the scFv portion on the T-cell surface, transduced T cells were incubated with biotinlabeled goat anti-mouse (Fab)2 polyclonal antibody or normal polyclonal goat immunoglobulin G (IgG) antibody as an isotype control, followed by staining with allophycocyanin (APC)-conjugated streptavidin. Flow analysis indicated that the FLT3-CAR was successfully expressed on the cell surface of engineered T cells (Figure 1d) . A standard 4-h 51 Cr release assay was performed as previously described [9] [10] [11] [12] to detect cytotoxicity of FLT3-CAR T cells against six AML cell lines expressing FLT3 (MOLM-13, EOL1, Kasumi, OCI-AML3, MV4-11, THP1), which was substantial, and against one AML cell line lacking expression of FLT3 (U937), which was not significant (Figure 1e, Supplementary Figure 2 and data not shown). Non-infected and empty vector-transduced T cells showed no appreciable cytotoxicity (Figure 1e , Supplementary  Figure 2 and data not shown). We also found that FLT3-CAR T cells eradiated FLT3(+) AML cells in a time-dependent fashion (Supplementary Figure 3) . The ability of FLT3-CAR T cells to secrete interferon gamma (IFN-γ) upon recognition of AML cells was also assessed. For this purpose, AML cells were co-cultured with an equal number of FLT3-CAR T cells in 96-well V-bottom plates at 37°C for 24 h with either AML cell lines expressing FLT3 (MOLM-13 or EOL1) or with an AML cell line lacking expression of FLT3 (U937). Cell-free supernatants were collected and the levels of IFN-γ were measured by ELISA, as previously described. Supplementary Figures 5 and 6 ). Similar data were observed for patient samples with the genetic mutation of FLT3-ITD (Supplementary Figure 7) .
Next, we performed an in vivo treatment of AML-bearing mice. For this purpose, MOLM-13 cells, which are FLT3(+) were retrovirally transduced with Pinco-pGL3-luc/GFP virus expressing firefly luciferase and GFP-positive cells were FACS-sorted, yielding MOLM-13-GL3 cells. NOD scid gamma (NSG) mice were intravenously injected with 8 ×10 6 MOLM-13-GL3 cells in 400 μl of PBS via tail vein on day 0 to establish an orthotopic xenograft AML model. Mice were intravenously administered with 5 × 10 6 effector cells, that is, primary FLT3-CAR T cells or empty vector-transduced primary T cells, in 400 μl of PBS via tail vein injections for 3 times, weekly, starting at day 9. Mice were intraperitoneally infused with D-luciferin (150 mg/kg body weight), anesthetized with isoflurane, and imaged using the in vivo Imaging System (IVIS) with Living Image software (PerkinElmer, Hopkinton, MA, USA) on day 17 to determine the efficacy of the two doses. We observed that infusion of FLT3-CAR T cells showed significant anti-leukemic activity (Supplementary Figure 8) . We repeated this experiment with the MV4-11 AML mouse model, in which 5 × 10 6 tumor cells were injected and a low and a high dose of FLT3-CAR T cells, 2 × 10 5 and 3 × 10 6 per mouse, respectively, were administered. Results showed that both the low and the high dose of FLT3-CAR T cells had higher levels of antitumor activity against MV4-11 AML cells than empty-vector-transduced T cells (Supplementary Figure 9) . Also, we observed that three-weekly administrations of FLT3-CAR T cells prolonged the survival of MOLM-13-implanted mice to achieve a survival rate of 100% on day 80, when all mice were killed without evidence of leukemia (Figure 2c ). We also engrafted 5 × 10 6 patient PBMC containing~90% FLT3(+) primary AML patient blasts in NSG mice and performed weekly treatment for 3 weeks with 5 × 10 6 FLT3-CAR T cells per injection, starting at 66 days post tumor cell implantation. The data showed that FLT3-CAR T-cell treatment also resulted in a survival rate of 100% at day 120, while 100% of the mice in control-treated groups died by day 90 (Figure 2d 5 human CD34(+) HSCs isolated from cord blood were simultaneously i.v. injected into NSG mice expressing human IL-3, GM-CSF and SCF (that is, NSGS mice). One month and 3 months later, there was no difference in the quantity and proportion of human CD34(+) and differentiated mature lymphocytes (for example, NK and B cells) and myeloid cells (for example, dendritic cells) in mouse bone marrow of mice receiving FLT3-CAR T cells or empty vector-transduced T cells (Figure 2g and Supplementary Figure 13) . These data suggest that FLT3-CAR T cells do not affect the capacity for HSC engraftment and differentiation.
In this report, we describe the generation of a new CAR to arm T cells for the treatment of FLT3(+) AML, with our in vivo preclinical data showing 100% survival in orthotopic models of a human FLT3 (+) AML cell line and FLT3(+) primary AML blasts from patients. For patients with FLT3 expression on the surface of leukemic blasts, FLT3-CAR T cells could be considered for treatment of refractory disease or up front treatment in the elderly with AML, given their dismal prognosis with standard therapy. 1 Further, FLT3-CAR T cells could be considered following attainment of complete remission in patients deemed at a high risk of relapse. 13 AML patients whose blasts contain the FLT3-ITD might be especially suitable for the CAR T-cell therapy because of their poor prognosis 2, 4 and because the FLT3-CAR T cells generated in this study can target both WT and mutant FLT3.
Our data suggest that FLT3 is an AML-associated antigen that can be targeted by FLT3-CAR T cells. Other CAR T cells used for the treatment of AML recognize CD123 or CD33, which are highly expressed on some AML blasts but also on normal cells such as HSCs and partially differentiated myeloid cells.
14 Thus, the possibility of toxicity, including myeloablation, could occur. 14 Although our in vivo studies conducted in mice, which should have had a different cytokine profile as in humans, FLT3-CAR T cells may offer an alternative strategy for application of CAR T-cell therapy in AML because our data indicate that FLT3-CAR T cells do not deplete CD34(+) HSCs and preserve HSC differentiation, at least by the in vivo assays performed in this study. Utilizing multiple CARs to target different AML-associated antigens (for example, FLT3, CD123 and CD33) may also be necessary in many cases of AML, as some tumor-associated antigens may not be expressed on all leukemia cells or the entire leukemic stem cell population. Further, AML blasts may also lose surface expression of a particular tumor antigen under the pressure of CAR T therapy. 15, 16 In summary, our study showed that FLT3 can be targeted by FLT3-CAR T cells for the treatment FLT3(+) AML. FLT3-CAR T cells may provide a new immunotherapeutic approach for AML patients.
